immatics biotechnologies GmbH raised $58 million in a series E funding round from existing and new investors.
The company intends to use the funding to develop several T-cell based therapies. The company's main product line includes IMA101, IMA201 and other T-cell receptor candidates. The company will also continue its work on novel tumor targets for cancer immunotherapy, using its XPRESIDENT technology.
The series E funding includes investment from existing investors, Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others. Life sciences company Amgen Inc. also joined the funding round.
Amgen is already partnering with Immatics to develop cancer treatments.